反応式
[OH:1][C:2]1[CH:10]=[CH:9][C:8]([C:11]2[N:12]([C:37]([O:39][C:40]([CH3:43])([CH3:42])[CH3:41])=[O:38])[C:13]3[C:18]([CH:19]=2)=[CH:17][C:16]([CH2:20][N:21]2[CH2:26][CH2:25][N:24]([CH2:27][CH2:28][O:29][Si:30]([C:33]([CH3:36])([CH3:35])[CH3:34])([CH3:32])[CH3:31])[CH2:23][CH2:22]2)=[CH:15][CH:14]=3)=[C:7]2[C:3]=1[CH2:4][NH:5][C:6]2=[O:44].C(N(CC)CC)C.[F:52][C:53]([F:59])([F:58])[S:54](Cl)(=[O:56])=[O:55]>ClCCl>[F:52][C:53]([F:59])([F:58])[S:54]([O:1][C:2]1[CH:10]=[CH:9][C:8]([C:11]2[N:12]([C:37]([O:39][C:40]([CH3:43])([CH3:42])[CH3:41])=[O:38])[C:13]3[C:18]([CH:19]=2)=[CH:17][C:16]([CH2:20][N:21]2[CH2:22][CH2:23][N:24]([CH2:27][CH2:28][O:29][Si:30]([C:33]([CH3:36])([CH3:34])[CH3:35])([CH3:32])[CH3:31])[CH2:25][CH2:26]2)=[CH:15][CH:14]=3)=[C:7]2[C:3]=1[CH2:4][NH:5][C:6]2=[O:44])(=[O:56])=[O:55]参加物
5
反応物 3
生成物 1
試薬・触媒・溶媒 1
実験手順
In a similar manner to Step 1 of Example 299, 4-hydroxy-7-(1-(tert-butoxycarbonyl)-5-[4-(2-tert-butyldimethylsilyloxyethyl)pyperazin-1-ylmethyl]indol-2-yl)isoindolinone (150 mg, 0.240-mmol) was suspended in dichloromethane (6.0 mL), and the suspension was treated with triethylamine (0.167 mL, 1.20 mmol) and trifluoromethanesulfonyl chloride (0.046 mL, 0.43 mmol) under ice-cooling, followed by purification by preparative thin-layer chromatography (chloroform/methanol=13/1) to obtain 4-trifluoromethanesulfonyloxy-7-{1-(tert-butoxycarbonyl)-5-[4-(2-tert-butyldimethylsilyloxyethyl)pyperazin-1-ylmethyl]indol-2-yl}isoindolinone (139 mg, yield 77%).
後処理
- temperaturecooling
- customfollowed by purification by preparative thin-layer chromatography (chloroform/methanol=13/1)
出典と根拠
- ORDレコード
- ord-bd00f595929f45459f0139a881c76f6c
- 出典データセット
- uspto-grants-2010_06
- 特許番号
- US07745641B2
関連ノート
読み込み中…